Cancer Treatment Today

Desmoid tumorsdo not generally metastsize but can cause pain by locally invading nearby structures and damage nearby organs. Several new drugs are being research, among them  Nexavar (sorafenib). Establihsing a dose in children has been difficulat. A recent study of sorafenib in children with neurofabromatosis was not able to establish the minmally tolerated dose. A series from Sloan Kettering used sorafenib as first and later line therapy. Sixteen of 22 (∼70%) patients reported significant improvement of symptoms. At a median of 6 months (2-29) of treatment, the 6/24 (25%) patients had partial response (PR), 17/24 (70%) with stable disease, and 1 with progression and death. NCCN lists sorafenib on p. SARC-E.

For professional version see here